Y Intercept Hong Kong Ltd Purchases New Holdings in BioNTech SE (NASDAQ:BNTX)

Y Intercept Hong Kong Ltd acquired a new position in BioNTech SE (NASDAQ:BNTX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 6,046 shares of the company's stock, valued at approximately $718,000.

A number of other hedge funds have also recently made changes to their positions in the stock. XTX Topco Ltd purchased a new position in BioNTech during the 3rd quarter valued at about $459,000. State Street Corp lifted its position in shares of BioNTech by 2.0% during the third quarter. State Street Corp now owns 155,867 shares of the company's stock worth $18,512,000 after purchasing an additional 3,014 shares in the last quarter. Redmile Group LLC purchased a new position in shares of BioNTech in the third quarter valued at approximately $18,345,000. Polar Asset Management Partners Inc. acquired a new position in shares of BioNTech in the third quarter valued at approximately $14,834,000. Finally, Harbor Advisors LLC purchased a new stake in BioNTech during the 3rd quarter worth approximately $238,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and raised their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. HSBC lifted their target price on BioNTech from $97.00 to $136.00 and gave the company a "buy" rating in a report on Monday, October 7th. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and upped their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. Finally, Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $140.76.

BioNTech Stock Down 0.3 %

NASDAQ:BNTX traded down $0.31 during midday trading on Friday, hitting $120.38. 586,070 shares of the company were exchanged, compared to its average volume of 808,448. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a market capitalization of $28.62 billion, a PE ratio of -57.32 and a beta of 0.22. The company has a fifty day simple moving average of $113.86 and a 200 day simple moving average of $100.38.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. As a group, equities analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.